comprehensive -WSS

comprehensive

author：fashion 2025-09-06 01:58:22 - browse：7553

intarcia implant. -- health tech coverage from STAT — The matchstick-sized, implantable device from Intarcia Therapeutics releases a steady, continuous, and low-dose stream of a drug for diabetes. Stuart Isett/Fortune Brainstorm Health

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Intarcia called for the panel meeting because of those two rejections, seeking outside input on the FDA’s decision. FDA then granted Intarcia’s request. The agency is not bound to advisory panel decisions, though it tends to follow their advice.

Intarcia started developing its lead therapy, a small, skinny bar implanted under the skin, for type 2 diabetes patients in 2016. The implant delivers a glucose-controlling medicine called exenatide, a member of the GLP-1 drugs that have taken the diabetes and obesity markets by storm. Intarcia’s implant continuously administers the drug over six months, with the goal of improving patient adherence compared to Eli Lilly and Novo Nordisk’s weekly GLP-1 shots.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Eli Lilly buys Point Biopharma in radiopharmaceuticals play

entertainment

focus

WSS

3 questions for the future of Biden's cancer moonshot

What to expect at HLTH 2023, the health care industry conference

California’s proposed $25 per hour health care minimum wage

Colorectal cancer study finds potential in overlooked immune cell

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

New research casts further doubt on a common procedure used with IVF

hotspot

comprehensive

leisure time

Apple is now the first public company to be valued at $3 trillion

When women are denied an abortion, their children fare worse than peers

The high cost of giving birth even with insurance

It's time to get medical device identifiers over the finish line

Hollywood unions extend contract negotiations for actors

Charles Manson follower Leslie Van Houten released from prison after 53 years

In age of alternative facts, a scholarly course on calling out crap

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Jerome Adams on the need for new antivirals for Covid

NIH fellows want a pay raise. Will that mean less money for grants?

knowledge

It's time to get medical device identifiers over the finish line

Study: Pain burden is higher in Black NFL players than white ones

Oak trusses raised to roof of fire

Petition to FDA: Get the lead out of consumer hair dyes

FDA panel signals lack of confidence in Amgen cancer drug data

Chan Zuckerberg Biohub Chicago to focus on inflammation

entertainment

focus

leisure time

leisure time